A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia

Overview of attention for article published in Leukemia, June 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 1 news outlet
twitter: 1 X user

patent: 1 patent
guideline: 1 clinical guideline source

Readers on

mendeley: 56 Mendeley

So far, Altmetric has seen 1 X post from an account with 33 followers.

A phase II, multicentre trial of decitabine in higher-risk chron... https://t.co/ylueOiOD2T #clinicaltrials | 🚀 by https://t.co/CvIVX9T061

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.

Login to access the Sentiment Analysis related to this output.